0001326110-23-000114.txt : 20230906
0001326110-23-000114.hdr.sgml : 20230906
20230906194015
ACCESSION NUMBER: 0001326110-23-000114
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20230906
DATE AS OF CHANGE: 20230906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LAUER REGAN J
CENTRAL INDEX KEY: 0001200637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37507
FILM NUMBER: 231240700
MAIL ADDRESS:
STREET 1: 4250 EXECUTIVE SQUARE SUITE 300
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER NAME:
FORMER CONFORMED NAME: GALLAGHER REGAN J
DATE OF NAME CHANGE: 20021023
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ImmunityBio, Inc.
CENTRAL INDEX KEY: 0001326110
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 431979754
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3530 JOHN HOPKINS COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (844) 696-5235
MAIL ADDRESS:
STREET 1: 3530 JOHN HOPKINS COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: NantKwest, Inc.
DATE OF NAME CHANGE: 20150713
FORMER COMPANY:
FORMER CONFORMED NAME: Conkwest, Inc.
DATE OF NAME CHANGE: 20140416
FORMER COMPANY:
FORMER CONFORMED NAME: ZelleRx Corp
DATE OF NAME CHANGE: 20050504
4
1
wk-form4_1694043604.xml
FORM 4
X0508
4
2023-09-01
0
0001326110
ImmunityBio, Inc.
IBRX
0001200637
LAUER REGAN J
C/O IMMUNITYBIO, INC.
3530 JOHN HOPKINS COURT
SAN DIEGO
CA
92121
0
1
0
0
Chief Accounting Officer
0
Common Stock
2023-09-01
4
M
0
32872
0
A
53902
D
Restricted Stock Units
2023-09-01
4
M
0
32872
0
D
Common Stock
32872
32872
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024.
/s/ Jason Liljestrom, as Attorney-in-Fact
2023-09-06